Todd Brady, Aldeyra Therapeutics CEO
Aldeyra to run another trial for its dry eye disease drug as part of resubmission plans
Aldeyra Therapeutics is planning to resubmit an NDA for its dry eye disease drug in the second half of this year, though it’ll have to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
